MARKET

OGEN

OGEN

ORAGENICS
AMEX

Real-time Quotes | Nasdaq Last Sale

0.6200
-0.0173
-2.71%
Opening 10:28 09/20 EDT
OPEN
0.6220
PREV CLOSE
0.6373
HIGH
0.6338
LOW
0.6200
VOLUME
279.65K
TURNOVER
--
52 WEEK HIGH
1.800
52 WEEK LOW
0.3770
MARKET CAP
72.04M
P/E (TTM)
-2.7703
1D
5D
1M
3M
1Y
5Y
Oragenics Launches Animal Study For COVID-19 Vaccine Candidate
Benzinga · 4d ago
BRIEF-Oragenics Initiates COVID-19 Challenge Study Testing Multiple Formulations Of Its Vaccine Candidate
reuters.com · 5d ago
Oragenics Initiates COVID-19 Challenge Study Evaluating Multiple Formulations of its SARS-CoV-2 Vaccine Candidate
TAMPA, Fla., September 15, 2021--Oragenics Initiates COVID-19 Challenge Study Evaluating Multiple Formulations of its SARS-CoV-2 Vaccine Candidate
Business Wire · 5d ago
Oragenics Launches Challenge Study of COVID-19 Vaccine Candidate in Hamsters
MT Newswires · 5d ago
Powerful Software Plays a key Role in Keeping the Pandemic at Bay
/PRNewswire/ -- The pandemic has helped to increase awareness of the importance of maintaining hygiene to avoid transmission of pathogens in healthcare facilities and among the general populous. According to data provided by , the global personal protectiv...
PR Newswire - PRF · 09/08 13:00
Company News for Aug 31, 2021
Companies in the news are: DSPG, IDEX, OGEN, AFRM
Zacks · 08/31 13:15
Oragenics's New Preclinical Data Supports Its Approach For COVID-19 Vaccine Development
Benzinga · 08/30 14:06
Oragenics Announces The Stabilized Pre-Fusion Spike Protein Trimer Produced By Its Canadian Collaborator And Licensed By The Company From The National Institutes Of Health Generates Neutralizing Antibodies In Mice After Immunization Against SARS-CoV-2
New data supports Company's approach to COVID-19 vaccine development. Oragenics, Inc. (NYSE:OGEN) (the Company) announces that the stabilized pre-fusion spike protein trimer produced by its Canadian
Benzinga · 08/30 11:34
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of OGEN. Analyze the recent business situations of ORAGENICS through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average OGEN stock price target is 2.250 with a high estimate of 2.250 and a low estimate of 2.250.
EPS
Institutional Holdings
Institutions: 18
Institutional Holdings: 6.33M
% Owned: 5.44%
Shares Outstanding: 116.19M
TypeInstitutionsShares
Increased
4
857.31K
New
5
128.78K
Decreased
2
2.71M
Sold Out
2
2.98M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.81%
Pharmaceuticals & Medical Research
-0.87%
Key Executives
Chairman/Executive Director
Frederick Telling
Chief Executive Officer/Chief Financial Officer/Treasurer/Secretary
Michael Sullivan
Director
Kim Murphy
Independent Director
Alan Dunton
Independent Director
Robert Koski
Independent Director
Charles Pope
No Data
  • All
  • Financials
  • Insiders
More
About OGEN
Oragenics, Inc. is a developing-stage company. The Company is focused on developing infectious diseases including coronaviruses and multidrug-resistant organisms. The Company’s pre-clinical product candidates includes OG716 and Terra CoV-2. It, through its subsidiary, is engaged in the research and development of Terra CoV-2 vaccine product candidate. It is also engaged in the development of its lead lantibiotic candidate, OG716, to treat Clostridium difficile.

Webull offers kinds of Oragenics Inc stock information, including AMEX:OGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OGEN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OGEN stock methods without spending real money on the virtual paper trading platform.